GeoVax Labs, Inc. (Nasdaq: GOVX) announced that its Chairman and Chief Executive Officer David Dodd will participate in a Tribe Public CEO Presentation and Q&A Webinar on May 28, 2026, focusing on building a resilient infectious disease preparedness strategy. The webinar, titled “Ebola, Marburg, Hantavirus, Mpox and Beyond: Building a Resilient Infectious Disease Preparedness Strategy,” will begin at 8:00 a.m. Pacific Time / 11:00 a.m. Eastern Time.
According to the press release, Dodd will discuss the limitations of current reactive approaches to emerging viral threats and the potential of platform-based vaccine technologies. “Ebola, Marburg, Mpox and most recently Hantavirus concerns all reinforce the same lesson: global preparedness strategies must evolve beyond reactive, single-threat approaches,” Dodd said. “GeoVax is focused on advancing versatile MVA-based vaccine technologies designed to support broader infectious disease preparedness and help address critical gaps in domestic and global biodefense infrastructure.”
The webinar is expected to address the growing importance of platform-based vaccine technologies, why emerging outbreaks continue to expose vulnerabilities in global response infrastructure, the potential applicability of Modified Vaccinia Ankara (MVA)-based technologies across multiple viral threats—including orthopox and hemorrhagic fever viruses—and the importance of scalable and resilient domestic vaccine manufacturing capabilities.
GeoVax’s priority program is GEO-MVA, an MVA-based vaccine targeting mpox and smallpox. The program is advancing under an expedited regulatory pathway, with plans to initiate a pivotal Phase 3 clinical trial in the second half of 2026. This trial aims to address critical global needs for expanded orthopoxvirus vaccine supply and biodefense preparedness.
The announcement comes amid recent Hantavirus concerns and ongoing threats from Ebola, Marburg, and Mpox, highlighting the need for versatile vaccine platforms that can be rapidly adapted to new pathogens. The ability to repurpose MVA-based technologies could significantly enhance response times during future outbreaks.
Registration for the complimentary Zoom webinar is available at Ebola-May-2026.TribePublic.com. Participants may submit questions in advance to research@tribepublic.com or during the live webinar using Zoom’s chat feature. Tribe Public Managing Member John F. Heerdink, Jr. will host the event and moderate audience questions.
GeoVax Labs is a clinical-stage biotechnology company focused on vaccines and immunotherapies for infectious diseases and cancer. Its MVA-based technology platform is central to its infectious disease strategy, while in oncology, the company is developing Gedeptin®, a gene-directed enzyme prodrug therapy for advanced head and neck cancer. For more information, visit www.geovax.com.
Tribe Public LLC facilitates corporate-sponsored webinars and investor engagement events, with a membership community including family offices, portfolio managers, accredited investors, analysts, and media professionals. More details are available at www.tribepublic.com.
This news story relied on content distributed by NewMediaWire. Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is GeoVax CEO to Discuss Platform-Based Vaccine Technologies in Tribe Public Webinar.